Drug Profile
SK PC B70M
Alternative Names: SK-PC-B70MLatest Information Update: 04 Oct 2017
Price :
$50
*
At a glance
- Originator SK Chemicals
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 04 Oct 2017 Discontinued - Phase-III for Alzheimer's disease in South Korea (unspecified route), because no recent reports on development identified further to phase III completion
- 01 Aug 2013 SK Chemicals completes a phase III trial in Alzheimer's disease in South Korea (NCT01249196)
- 31 May 2010 Phase-III clinical trials in Alzheimer's disease in South Korea (unspecified route)